The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | 12-month primary endpoint analysis from the Phase III ROP-ET study of ropeginterferon alfa-2b in ET
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discusses the 12-month primary endpoint analysis from the Phase III ROP-ET study (NCT06514807) of ropeginterferon alfa-2b in essential thrombocythemia (ET). Prof. Kiladjian notes that the treatment achieved durable responses and was well-tolerated. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
